KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Leases (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Current Leases for 5 consecutive years, with $16.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 9.26% year-over-year to $16.3 million, compared with a TTM value of $16.3 million through Sep 2025, up 9.26%, and an annual FY2024 reading of $14.0 million, down 3.85% over the prior year.
  • Current Leases was $16.3 million for Q3 2025 at Aurinia Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $16.3 million in Q3 2025 and bottomed at $918000.0 in Q3 2022.
  • Average Current Leases over 5 years is $6.4 million, with a median of $1.1 million recorded in 2021.
  • Peak annual rise in Current Leases hit 1423.16% in 2024, while the deepest fall reached 92.81% in 2024.
  • Year by year, Current Leases stood at $1.1 million in 2021, then fell by 13.31% to $918000.0 in 2022, then soared by 1491.39% to $14.6 million in 2023, then decreased by 3.85% to $14.0 million in 2024, then increased by 16.11% to $16.3 million in 2025.
  • Business Quant data shows Current Leases for AUPH at $16.3 million in Q3 2025, $1.0 million in Q2 2025, and $1.0 million in Q1 2025.